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Abstract
Background: Online drug information databases are used to assist in enhancing clinical decision
support. However, the choice of which online database to consult, purchase or subscribe to is likely
made based on subjective elements such as history of use, familiarity, or availability during
professional training. The purpose of this study was to evaluate clinical decision support tools for
drug information by systematically comparing the most commonly used online drug information
databases.
Methods: Five commercially available and two freely available online drug information databases
were evaluated according to scope (presence or absence of answer), completeness (the
comprehensiveness of the answers), and ease of use. Additionally, a composite score integrating all
three criteria was utilized. Fifteen weighted categories comprised of 158 questions were used to
conduct the analysis. Descriptive statistics and Chi-square were used to summarize the evaluation
components and make comparisons between databases. Scheffe's multiple comparison procedure
was used to determine statistically different scope and completeness scores. The composite score
was subjected to sensitivity analysis to investigate the effect of the choice of percentages for scope
and completeness.
Results: The rankings for the databases from highest to lowest, based on composite scores were
Clinical Pharmacology, Micromedex, Lexi-Comp Online, Facts & Comparisons 4.0, Epocrates
Online Premium, RxList.com, and Epocrates Online Free. Differences in scope produced three
statistical groupings with Group 1 (best) performers being: Clinical Pharmacology, Micromedex,
Facts & Comparisons 4.0, Lexi-Comp Online, Group 2: Epocrates Premium and RxList.com and
Group 3: Epocrates Free (p < 0.05). Completeness scores were similarly stratified. Collapsing the
databases into two groups by access (subscription or free), showed the subscription databases
performed better than the free databases in the measured criteria (p < 0.001).
Conclusion: Online drug information databases, which belong to clinical decision support, vary in
their ability to answer questions across a range of categories.
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Background
Considering the estimate that the entire body of medical
knowledge doubles every two years, it is no surprise that
health information technology and computer-based deci-
sion support resources have been targeted for their poten-
tial value in enhancing safety and improving patient
outcomes [1,2]. In addition to online databases that pro-
vide access to the primary literature such as Medline, com-
mercially available databases are often used to assist with
decision making. One example of resources is the online
drug information databases. These drug information data-
bases are used to assist in enhancing clinical decision sup-
port regarding a number of patient-related therapeutic
choices including: determining weight-based or renally-
impaired dosing regimens, monitoring for drug interac-
tions, and identifying safety risks [3]. However, the choice
of which commercial database to consult, purchase or
subscribe to is likely made based on subjective elements
such as history of use, familiarity, or availability during
professional training. A handful of evaluations of these
types of resources have been undertaken including a for-
ward-thinking paper published in 1997 which focused on
evaluating electronic databases for questions specific to
decentralized pharmacists [4]. Another article looked at
several drug databases from the perspective of librarians
and pharmacists, but used only ten questions in their
assessment and omitted some of the most commonly
used databases [5]. Finally, a few recent articles have been
published which examined a narrow spectrum such as
electronic or online databases used for identifying pre-
scription and over-the-counter (OTC) solid dosage forms
and herb-drug interactions [6-8]. None of those articles
targeted overall drug database use by healthcare practi-
tioners nor were they comprehensive in their database
selection. Thus, there is nothing in the published litera-
ture that provides a systematic and objective evaluation of
the clinical decision support tool this article focused on –
the online drug database. Additionally, no studies have
been published comparing commercially available and
freely available online drug databases.
Objective
The objective of this study was to evaluate clinical deci-
sion support tools for drug information by systematically




There are three primary categories of online drug data-
bases: Category 1: comprehensive; Category 2: full-text
versions of an electronic book; and Category 3: freely
available online databases [9]. Our primary focus was to
assess the comprehensive databases that are most com-
monly used in a clinical decision support role by health-
care professionals. In order to determine database
inclusion in the analysis, several factors were considered
including: 1) usage rates in hospitals, clinics, and aca-
demic institutions, 2) previously published subjective
reviews, and 3) online accessibility.
It was also determined that the online drug databases
selected for inclusion should provide comprehensive
information about drug therapy and contain the types of
information needed across the healthcare spectrum. Addi-
tional features of the databases such as calculators, treat-
ment algorithms, and other value-added functions would
not be examined in this evaluation. Databases containing
information to answer questions of particular importance
to pharmacists and physicians were emphasized [10]. Five
subscription databases satisfied our criteria including:
Clinical Pharmacology, Epocrates Online Premium, Facts
& Comparisons 4.0, Lexi-Comp Online, and Micromedex.
For a secondary focus, we also selected two Category 3
(freely available) databases including Epocrates Online
Free and RxList.com. Some databases that we examined
have different bundles, or packages of components, avail-
able for purchase. We elected to compare the baseline
bundles of all databases when applicable. The details of
each database package can be found in Table 1.
Question development
Fifteen categories of drug information questions (e.g. drug
dosing, drug interactions, mechanism of action/pharma-
cology, side effects, and over-the-counter drug informa-
tion) were identified as important to healthcare
professionals based on the published literature and the
Nova Southeastern University Drug Information Centers'
records of queries by primary care providers. The number
of questions placed in each category was weighted, with
more important categories receiving more questions. For
example, a category directly tied to patient safety such as
drug interactions contained 17 questions, whereas the for-
eign drug identification category included only 7 ques-
tions. Questions were written by the authors and then
reviewed by pharmacists representing different disci-
plines. Following feedback from the reviewers, a grand
total of 158 representative questions populated the cate-
gories. Answers for the selected questions were verified
against a minimum of one 'gold standard' resource such
as the package insert or Physician's Desk Reference (PDR)
and information located in the primary literature.
Answers for questions that were not typically covered by
the PDR such as off-label indications were generated from
sources such as the United States Pharmacopeia and the
primary literature.
The questions were used to evaluate the functionality of
the databases, specifically by scope, completeness, and
ease of use (EOU). Scope was assessed by the presence orBMC Medical Informatics and Decision Making 2007, 7:7 http://www.biomedcentral.com/1472-6947/7/7
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absence of an answer for each question and assigned a
value of one or zero accordingly. A three-point scale was
used to evaluate completeness with one being least com-
plete and three being most complete. Ease of use was
measured by the number of clicks or steps necessary to
reach the answer. The most direct method or shortest
route to each answer was reported for ease of use. A com-
posite score of the three facets was also generated by
weighting the scope 70% and completeness 30%. Then,
the EOU score was subtracted from the weighted value to
determine the final score.
Assessment techniques
All databases were evaluated by two authors in November
2005. When a discrepancy occurred in scoring, usually
regarding completeness, the issue was discussed until a
consensus was reached. The percentages for each evalua-
tive component, along with mean scores and tabulated
raw scores were compiled. Scope, completeness, ease of
use and composite scores were all compared between
databases using Scheffe's post-hoc multiple comparison
test and the Chi-square test. The composite score was sub-
jected to sensitivity analysis to investigate the effect of the
choice of percentages for scope and completeness. Com-




The scope evaluation component was designed to deter-
mine if a correct answer was present in the database for
each corresponding question. The scores for scope are pre-
sented as a mean and a percentage for each of the fifteen
question categories (Table 2). The databases able to
answer the largest percentage of all 158 questions were:
Clinical Pharmacology (86.7%), Micromedex (83.5%),
Table 2: Scope of Databases
Scope Score n CP EP FC LC MM EF RL
Dosage/Schedule 17 16 13 14 13 15 12 11
Drug Interactions 17 14 13 14 13 15 12 12
Methods of Administration 13 12 12 12 12 13 10 12
Adverse Drug Reactions 13 13 91 2 1 2 13 91 0
Over-the-Counter 13 11 4 11 9643
Indications/Unlabeled Uses 11 11 6 8 10 10 6 5
Identification/Content 10 10 789858
Pharmacokinetics 10 8 5 9 8 9 36
Compatibility/Stability 98 469 816
Contraindications 9 9 6879 58
Dietary Supplements 8 8 7 8 6 8 05
Pharmacology/MOA 8 8 7 88778
Pregnancy and Lactation 87 68886 8
Foreign Drug Identification 71 013300
Cost and Economics 514 1 4 0 4 1
Totals 158 137 103 128 131 132 84 103
(%) 86.7 65.2 81.0 82.9 83.5 53.2 65.2
n = number of questions per category, CP = Clinical Pharmacology, EP = Epocrates Premium, FC = Facts & Comparisons 4.0, LC = Lexi-Comp 
Online, MM = Micromedex, EF = Epocrates Free, RL = RxList
Table 1: Baseline Bundles and Components Evaluated
Subscription Databases:
Clinical Pharmacology Drug Information Database and Drug Interaction Analyzer
Epocrates Online Premium Epocrates drug information database content plus dietary supplement information, pill identifier, patient 
information
Facts & Comparisons 4.0 Drug Facts & Comparisons, Drug Interaction Facts, The Review of Natural Products, Nonprescription Drug 
Therapy, MedFacts, Drug Interaction Facts: Herbal Supplements and Food, Drug Identification Tool, A to Z 
Drug Facts
Lexi-Comp Online Lexi-Drugs, Pediatric Lexi-Drugs, Geriatric Lexi-Drugs, Natural Products, Pharmacogenomics, Infectious 
Diseases, Poisoning and Toxicology, Nuclear, Biological and Chemical Agent Exposures, Laboratory Tests
Micromedex DRUGDEX (Drug Evaluations, Drug Consults), Identidex
Free Databases:
Epocrates Online Free Epocrates drug information database content
RxList.com Internet site with information sourced from WebMD and FirstDataBankBMC Medical Informatics and Decision Making 2007, 7:7 http://www.biomedcentral.com/1472-6947/7/7
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Lexi-Comp Online (82.9%) and Facts & Comparisons 4.0
(81.0%). Pair-wise comparisons revealed three discrete
tiers of database performance including: Tier 1 (Scope
128–137), Tier 2 (Scope 103 and 103) and Tier 3 (Scope
84) which were all significantly different from each other
(p < .05). Databases did not get credit for providing an
incorrect or misleading answer; however, they also did
not suffer a penalty or negative score (such as subtracting
one point from scope). There were very few cases of erro-
neous information in the databases.
Completeness
Completeness was used to assess how comprehensive the
database was in terms of its ability to answer each ques-
tion. A three-point scale was used with a score of one indi-
cating a cursory answer and three indicating a complete,
correct answer. Many questions were structured in such a
way that they would receive a completeness score of '3' if
they had a scope score of '1' (e.g. What is the bioavailabil-
ity of oral levofloxacin? 99%). If an answer had two com-
ponents (e.g. Is lamivudine used to prevent human
immunodeficiency virus (HIV) following accidental
needlesticks? Yes, it is an off-label use) then completeness
would be scored either a '2' or a '3'. For questions requir-
ing three or more components to provide a complete
answer, the completeness score was assigned accordingly
(e.g. What is the recommended dose of lepirudin for
heparin-induced thrombocytopenia? (0.4 mg/kg up to
110 kg as a bolus, then 0.15 mg/kg up to 110 kg infusion.
Dose is adjusted based on an activated partial thrombo-
plastin time (aPTT) ratio). Completeness scores were only
assigned if there was a score for scope. Therefore, ques-
tions which had a score of zero for scope were not given a
score of zero for completeness. The performance of the
databases for completeness is reported in Table 3. Also
similar to the scores for Scope, results for Completeness
were stratified according to the same clustered Tier system
and had the same occupants.
Ease of use
Ease of use was designed to measure how simple, direct,
and user-friendly the database would be under optimal
conditions. Optimal conditions were defined as the fastest
possible route from the initial database screen to the
desired answer. Several other options were considered for
measuring EOU based on previous evaluations such as a
visual analogue scale (VAS), two comprehensive ques-
tions with Likert-scale ratings, and time (in seconds)
[4,5,11]. However, in order to use a more systematic and
comprehensive approach, we chose the previously
employed method of the number of steps or clicks to
reach the answer in order to be as objective as possible
and to reduce confounders such as a 'learning curve'[12].
This direct approach may not mimic the path that inexpe-
rienced users with the databases would take, but it was
deemed to be the best alternative. The mean numbers of
clicks or steps were as follows: Epocrates Online Free
(1.66), Epocrates Online Premium (1.72), Lexi-Comp
Online (2.16), Micromedex (2.70), Facts & Comparisons
4.0 (3.02), Clinical Pharmacology (3.50), and RxList.com
(3.17). Full results for ease of use are listed in Table 4.
Note that the fewer the number of steps necessary, the
faster and easier the information could be accessed.
Composite Scores
In order to integrate all of the different evaluation criteria,
a composite score was calculated from the scope, com-
pleteness and ease of use scores. Clinical Pharmacology
earned the highest score followed by Micromedex, Lexi-
Comp Online, and Facts & Comparisons 4.0. Full results
are presented in Table 5. A sensitivity analysis was per-
formed around the choice of the weighting of the scope
and completeness score (70% and 30%). Varying the
weighting factor to 60–40 and 50–50, did not change the
ordering of the databases by composite score.
Subscription vs. Free Online Databases
The mean scope of the subscription databases was com-
pared to that of the free databases. The subscription data-
bases were found to have a statistically broader scope than
the free databases (p < .01).
Errors
Of the 158 questions across the seven databases that were
evaluated, there were only three cases in which the infor-
mation provided by the database was different than those
defined as correct by the references outlined previously for
answer generation. The conflicting answers were primarily
in the Dosage/Schedule section. There were two answers
from RxList.com that differed with the gold standard ref-
erence. For the question: "What is the dose of potassium
iodide for a 6-year-old in a radiation emergency with
exposure > 5 cGy?", the database stated the dose to be 100
mg. The correct answer is 65 mg daily. The second errone-
ous answer provided by RxList.com fell under the OTC
category, but was again a dosage related error. For the
question: "What is the OTC weight-based dose of ibupro-
fen for a child weighing 35–47 pounds?" the database
provided a chart with the answer as 100 mg every 6 to 8
hours, while the correct answer should have been 150 mg
every 6 to 8 hours. The question, "What is the recom-
mended dose of paroxetine for general anxiety disorder?"
was answered by Clinical Pharmacology as "initially, 10
mg PO once daily, usually in the morning. Doses should
be increased by 10 mg/day at weekly intervals if needed
and tolerated. The target dose is 40 mg PO once daily and
maximum dose is 60 mg/day." The answer based on the
gold standard is, "the recommended starting dosage and
the established effective dosage is 20 mg/day. There is notBMC Medical Informatics and Decision Making 2007, 7:7 http://www.biomedcentral.com/1472-6947/7/7
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sufficient evidence to suggest a greater benefit to doses
higher than 20 mg/day."
Discussion
Healthcare professionals are constantly pressured to
maintain and expand the knowledge base of their chosen
specialty as well as an ever-increasing number of drug
therapies – which include prescription pharmaceuticals,
OTCs and dietary supplements including herbal products.
Professionals must make clinical decisions and imple-
ment treatment plans integrating these therapies every
day. One way to assist in that decision-making process is
to employ tools such as an online drug information data-
base. Thus, the choice of which clinical decision support
tool is consulted could indirectly and directly impact
patient care and outcomes. Factually correct and complete
drug information that is easily accessible should be the
paramount considerations in selecting an online data-
base. Our study analyzed seven commercially available
databases according to these criteria and found that the
best performers included: Clinical Pharmacology, Micro-
medex, Lexi-Comp Online, and Facts & Comparisons 4.0.
Table 4: Ease of Use of Databases
Ease of Use Score CP EP FC LC MM EF RL
Dosage/Schedule 3.94 1.54 3.00 2.00 2.80 1.58 3.09
Drug Interactions 4.07 2.77 3.00 2.31 2.40 2.92 3.42
Methods of Administration 3.00 1.33 3.00 2.00 2.54 1.30 3.25
Adverse Drug Reactions 3.62 1.78 3.00 2.00 2.69 1.78 3.00
Over-the-Counter 4.25 1.75 3.00 2.00 3.00 1.75 4.33
Indications/Unlabeled Uses 3.55 1.50 3.00 2.00 2.90 1.50 3.00
Identification/Content 3.10 1.43 1.88 2.44 2.38 1.40 1.63
Pharmacokinetics 2.63 1.60 3.44 2.00 2.89 1.33 3.00
Compatibility/Stability 3.50 2.25 3.17 2.00 2.75 1.00 3.00
Contraindications 3.33 1.33 3.00 2.33 2.78 1.20 2.88
Dietary Supplements 3.25 2.29 3.00 2.67 2.25 NA 3.00
Pharmacology/MOA 2.00 1.00 3.00 2.00 3.00 1.00 3.00
Pregnancy and Lactation 3.00 1.17 3.00 2.00 2.75 1.33 3.00
Foreign Drug Identification 4.00 NA 3.00 2.00 3.33 NA NA
Cost and Economics 14.00 2.0 10.00 3.75 NA 2.00 20.00
Mean number of steps required 3.50 1.72 3.02 2.16 2.70 1.66 3.17
CP = Clinical Pharmacology, EP = Epocrates Premium, FC = Facts & Comparisons 4.0, LC = Lexi-Comp Online, MM = Micromedex, EF = Epocrates 
Free, RL = RxList, NA = no score/no answer present
Table 3: Completeness of Databases
Completeness Score CP EP FC LC MM EF RL
Dosage/Schedule 2.88 2.92 2.93 2.92 3.00 2.92 3.00
Drug Interactions 2.93 2.69 2.79 2.77 3.00 2.67 2.42
Methods of Administration 2.92 2.67 2.92 3.00 2.92 2.60 2.58
Adverse Drug Reactions 2.69 2.89 2.92 2.92 3.00 2.89 2.40
Over-the-Counter 2.73 2.75 2.64 2.89 2.17 2.75 2.33
Indications/Unlabeled Uses 3.00 2.67 3.00 3.00 3.00 2.67 3.00
Identification/Content 2.90 2.86 2.88 2.89 2.88 2.80 2.88
Pharmacokinetics 2.88 2.60 2.89 2.63 2.67 3.00 2.50
Compatibility/Stability 2.88 2.75 2.83 2.89 3.00 3.00 2.67
Contraindications 3.00 3.00 3.00 2.86 2.89 3.00 2.75
Dietary Supplements 3.00 2.86 2.88 2.33 3.00 NA 2.80
Pharmacology/MOA 2.88 2.71 3.00 2.63 3.00 2.71 3.00
Pregnancy and Lactation 3.00 2.83 3.00 3.00 2.88 2.83 2.63
Foreign Drug Identification 3.00 NA 1.00 3.00 3.00 NA NA
Cost and Economics 3.00 3.00 3.00 3.00 NA 3.00 3.00
(%) 96.4 93.2 95.8 95.2 97.0 93.2 89.6
CP = Clinical Pharmacology, EP = Epocrates Premium, FC = Facts & Comparisons 4.0, LC = Lexi-Comp Online, MM = Micromedex, EF = Epocrates 
Free, RL = RxList, NA = no score/no answer presentBMC Medical Informatics and Decision Making 2007, 7:7 http://www.biomedcentral.com/1472-6947/7/7
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However, for the eight top categories of questions, two of
the seven databases accounted for or tied all of the high
scores for scope. Clinical Pharmacology scored the highest
in three and tied for two high scores and Micromedex had
the top score for two and tied for two. In an effort to fur-
ther put the data into context, raw and composite scores
were examined and tests were performed to measure for
differences. While the descriptive statistics indicated a top
performer and a rank order to all 8 databases, direct com-
parisons produced 3 groupings (tiers) of databases that
were statistically different. All databases within a tier were
found to be statistically similar.
However, given the significant difference in cost between
databases, a finding of similarity is very significant. For
many individuals and institutions, cost is part of the
inherent value of these types of tools along with the antic-
ipated number of users and format availability such as
personal digital assistants (PDAs). For example, Microme-
dex and Clinical Pharmacology both include abridged
PDA versions of their databases as part of their base insti-
tutional subscription package whereas Lexi-Comp Online
does not.
In order to judge which online database would be the best
match for an individual practitioner or institution, addi-
tional criteria should be considered. One way to utilize
the results from this study is to look at how each database
scored in specific categories and combine those results
with practice-specific priorities. For example, some data-
bases did particularly well (or poorly) with safety-focused
questions, questions about dietary supplements, or ques-
tions reflective of a diverse patient population such as for-
eign drug identification. Over-the-counter drug
considerations is another category in which there was a lot
of variability, with scores ranging from three to eleven out
of a possible thirteen. Despite being overlooked in medi-
cal histories, as treatment options, and as offending or
causative agents in side effects and interactions, some
databases still fail to include OTC information [13-15].
Limitations
Most of the databases evaluated offer additional value-
added functions and references beyond the baseline drug
information that was measured in this study. Some have
extensive calculator functions, diagnostic criteria and
tools, patient education components, and formulary
information. None of them were assessed in this study.
Those additional components may have a direct impact
on the decision-making process when selecting an online
database. However, it was outside the intended scope to
include them in this evaluation.
All of the databases that were analyzed in this study are
updated and changed with varying frequencies. Thus, the
information that was present at the time of the evaluation
for each database may not be true now or in the future.
This analysis represents a snapshot of the quality and
accessibility of drug information each database provided
at the time of the study.
The ease of use criteria certainly provides guidance for
which databases are the most user-friendly; however,
another element must be considered when examining the
scores. The number of clicks or steps to find the answer
may not take everything into account for the total time to
retrieve an answer. Once the target section of the drug
monograph had been reached, credit was given to the
database. Therefore, a database that requires a fewer
number of clicks but then requires considerable scrolling
would score better than one that required more clicks but
took you directly to the desired information. In practice,
the total time devoted to each could be very similar. For
example, an answer was located within Micromedex in an
average of 2.70 steps. However, Micromedex provided the
drug monograph in its entirety so the user must scroll
through the monograph to locate the desired answer, or
use the quick links to jump to a specific section within the
monograph, thus adding steps to the process. Clinical
Pharmacology scored an average of 3.50 steps to reach the
desired answer. With this database, each click narrows the
information provided and takes the user to a specific sec-
tion of the monograph, rather than the monograph in its
entirety. While one method of data organization and
retrieval is not necessarily better than another, it should
be considered when choosing a database. The amount of
data the user must review before actually finding the
desired information can greatly influence the speed of
Table 5: Composite Scores of Online Drug Databases
Composite Score CP EP FC LC MM EF RL
Mean Scope 86.7 65.2 81.0 82.9 83.5 53.2 65.2
Mean Completeness 96.4 93.2 95.8 95.2 97.0 93.2 89.6
Scope (0.7) + Completeness (0.30) 89.6 73.6 85.4 86.6 87.5 65.2 72.5
Mean number of steps - 1 2.50 0.70 2.02 1.16 1.75 0.55 2.17
Scope (0.7) + Completeness (0.30) - (Ease of Use - 1) = Composite Score 87.1 72.9 83.4 85.4 85.8 64.5 70.3
CP = Clinical Pharmacology, EP = Epocrates Premium, FC = Facts & Comparisons 4.0, LC = Lexi-Comp Online, MM = Micromedex, EF = Epocrates 
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retrieval and overall utility of the database. Despite the
limitations, the authors maintain that the ease of use cri-
teria remains the most consistent and most easily repro-
ducible method of the choices available.
We included a robust number of questions, especially rel-
ative to other evaluative studies with a similar structure; to
further differentiate between databases would require a
larger sample of questions [5,10,11]. In support of this
possibility, it is notable that most of the widest margins
between databases occurred when there were categories
with 10 or more questions. We also acknowledge that an
evaluation conducted with an entirely different set of
questions could result in different findings.
Conclusion
The online drug information databases we have evaluated
and which belong to clinical decision support vary in their
ability to answer questions across a range of categories.
Ranked according to composite score, Clinical Pharma-
cology, Micromedex, Lexi-Comp Online, and Facts &
Comparisons 4.0 were the top ranked online information
databases. Additionally, the databases that require a sub-
scription outperformed the free online databases.
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